2024-11-01 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**1. Relative Performance:**

Eli Lilly and Co (LLY) has significantly outperformed the S&P 500 (VOO) with a cumulative return of 790.13% compared to VOO's 131.38%.  The current outperformance is 658.75% which represents 82.09% of the maximum historical outperformance range, indicating strong relative performance over time.

**2. Recent Price Movement:**

* **Closing Price:** $829.74 (Last-market: $830.15)
* **5-day Moving Average:** $873.69
* **20-day Moving Average:** $901.72
* **60-day Moving Average:** $913.57

The current price is below all moving averages, suggesting a potential downtrend or consolidation phase.

**3. Technical Indicators:**

* **RSI:** 14.02 -  The RSI is extremely low, indicating the stock is oversold.
* **PPO:** -0.85 -  The PPO is negative, indicating a potential bearish trend.
* **Delta_Previous_Relative_Divergence:** -7.23 (-) - This indicates a short-term downtrend in relative performance.
* **Expected Return:** 97.48% - This suggests a high potential for long-term outperformance compared to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2024-10-30 | -0.06 | 9.50 B$ |

The most recent earnings report (2024-10-30) showed an EPS of 1.08, exceeding analyst expectations. This reflects continued strong growth for Eli Lilly.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-06-30 | $11.30B | 80.80% |
| 2024-03-31  | $8.77B | 80.91% |
| 2023-12-31  | $9.35B | 80.88% |
| 2023-09-30  | $9.50B | 80.42% |
| 2023-06-30  | $8.31B | 78.26% |

Eli Lilly has shown consistent revenue and profit growth, demonstrating a robust and profitable business model.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $13.56B | 21.88% |
| 2024-03-31 | $12.81B | 17.51% |
| 2023-12-31 | $10.77B | 20.33% |
| 2023-09-30 | $11.22B | -0.51% |
| 2023-06-30 | $11.06B | 15.94% |

The company demonstrates strong capital management and a healthy return on equity.

**6. News and Recent Issues:**

* Recent Earnings News: The most recent earnings report for the third quarter of 2024, released on October 30th, exceeded analyst expectations with an EPS of 1.08, leading to a positive market response.

* Recent Market Outlook: Eli Lilly continues to be a leader in the pharmaceutical industry, with its diverse portfolio of products and strong growth prospects. The recent positive earnings report indicates continued momentum and reinforces the company's position as a valuable investment.

* Analyst Opinions and Performance Highlights:  Eli Lilly is generally viewed favorably by analysts, with most analysts holding a "buy" or "strong buy" rating.  Recent reports highlight the company's strong pipeline of potential new drugs and its solid financial performance.

**7. Summary:**

Eli Lilly and Co (LLY) is a strong performer, demonstrating consistent revenue and profit growth, and outperforming the S&P 500. The company has a strong financial position and a promising future driven by its innovative drug pipeline. The current oversold conditions and downtrend in relative performance might present an opportunity for investors, especially considering the long-term growth potential. However, investors should remain cautious and monitor the company's future developments. 
